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ABSTRACT
Clinical trials are widely adopted for the purpose of evaluating
medical research. In particular, they are used to study various as-
pects of medical science, as well as being a vital stage in the deploy-
ment of new drug treatments. However, a review of the UK Medical
Research Council found that only 31% of trials actually recruited
to their planned target, with 30–40% of costs arising during the re-
cruitment phase alone. This is mainly due to the challenges that are
involved in designing the clinical trial, and recruiting the required
number of patients for this trial within a certain time-frame. Both
tasks create significant overhead as they are slow and costly. In re-
sponse, we propose a multi-agent architecture that helps ease the
process of recruiting patients for clinical trials. This paper presents
a results from a deployment of the architecture, showing that it suc-
ceeds in recruiting a sufficient number of patients for multiple clin-
ical trials. The results also show that recruitment is better for some
trials than for others, due to the differing trial requirements and
recruitment processes.
Categories and Subject Descriptors
I.2.11 [Distributed Artificial Intelligence]: Multiagent systems
General Terms
Design, Performance
Keywords
Healthcare Application, Multi-Agent, Evaluation
1. INTRODUCTION
Clinical trials are the gold standard by which medical research
is evaluated. They involve the controlled testing of treatments on
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patients who match certain criteria, e.g. age, gender, ailment. The
stringent nature of these criteria, however, mean that many trials are
unsuccessful in recruiting sufficient patients. A review of the UK
Medical Research Council found that only 31% of trials actually
recruited to their planned target, with 30–40% of costs arising dur-
ing the recruitment phase alone [7], as discovering and contacting
eligible potential recruits are logistically and legally challenging.
Consequently, many research projects take far longer to complete
than is desirable (or, in the worst case, not at all).
Currently, patient recruitment is performed in a laborious man-
ner, which is ill-suited for situations where many specialised pa-
tients are required. It often involves a human recruitment agent
visiting clinics in an attempt to locate suitable patients (e.g. ask-
ing practitioners or searching local medical records). This creates
significant overhead as it is both slow and costly, as well as non-
scalable for most trials.
With this challenge in mind, we began an effort to build a sys-
tem capable of facilitating clinical researchers in more effectively
recruiting patients for their trials. Through an extensive require-
ments elicitation process, in collaboration with the UK’s National
Health Service, we discovered that the recruitment process is not
only complex, but also crosses the boundaries of many different
legal entities. Typical trials can involve several organisations, each
containing many different professionals, including members of uni-
versities, government bodies, companies, regulation frameworks,
hospitals and various other primary care units. Each organisation
has different aims, as well as a variety of internal protocols that
must be followed. We believe this type of environment suits, ide-
ally, the strengths of agent-based design and, as such, this paper de-
tails the design, implementation and deployment of an agent-based
recruitment system for clinical trials, called ePCRN-IDEA.
The principle behind our work is simple: to replace human re-
cruitment agents with autonomous software agents. We have mod-
elled the processes of clinical trial recruitment using the GAIA
methodology [15], designing an agent-based system consisting of
all entities required to successfully discover, recruit and monitor
patients. We have implemented and deployed the majority of our
full design, placing our software agents in 31 primary care clin-
ics in the UK. Put simply, these agents monitor the patients seen
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within each clinic in real time, attempting to identify those who
could be recruited onto active trials. Whenever an eligible patients
visits a clinic, the General Practitioner (GP) is notified and asked
to undertake a simple online procedure to recruit the individual.
In collaboration with a number of other agents distributed in vari-
ous organisations, these agents have already recruited 230 patients.
This paper details our experiences during this process, describing
both our design and prototype implementation.
The rest of the paper is structured as follows. The background to
the research is discussed in Section 2, before introducing our model
of clinical trials in Section 3. Section 4 details the ePCRN-IDEA
recruitment system, Section 5 presents a prototype implementation,
and Section 6 contains an evaluation. We summarise the outcomes
in Section 7.
2. BACKGROUND
We begin by exploring the area of clinical trial recruitment be-
fore discussing, more generally, agents in healthcare. Following
this, we provide a brief description of the GAIA agent develop-
ment methodology, which we chose as the most appropriate for
designing ePCRN-IDEA.
2.1 Clinical Trial Recruitment
Clinical trials are a challenging stage in the research of clinicians
due to the complexity of recruiting patients for participation. Many
types of trials can suffer from such difficulties; for instance, trials
that have potential recruits who are widely distributed over many
clinics are extremely difficult to recruit for due to the intensive re-
source requirements. Studies show that 30% of participating clinics
fail to even recruit a single patient [10]. This can be exacerbated by
the complex eligibility requirements, or trials that require immedi-
ate actions, e.g. a change of drug treatments.
Clinical trial recruitment is performed by first defining eligibility
criteria that stipulate the exact characteristics that make a patient
eligible for participation, e.g. gender, age, ailments etc. It is then
necessary to discover patients who match the criteria, before con-
tacting and recruiting them. Traditionally, locating such patients is
achieved using one or more of the following approaches:
• Advertising and public relations: This involves using posters,
adverts and brochures to advertise eligibility criteria directly
to practitioners and patients.
• Recruiters: This involves sending human recruiters to clin-
ics, usually after feasibility modelling, analysis and site se-
lections, in an attempt to discover patients who match the
eligibility criteria.
• Practitioners: This involves doctors meeting periodically (of-
ten GPs) to discuss patient treatments and potential trials in
an attempt to spot eligible patients during consultation.
These methods are time consuming and expensive, particularly
for trials that have high patient targets, complex eligibility crite-
ria, rare diseases or involve emergency cases. This has led to the
development of Clinical Trial Alert (CTA) systems, which auto-
matically alert practitioners to the eligibility of a patient when they
are in consultation. Such systems allow the practitioner to immedi-
ately discuss the trial with the patient, to enable instant recruitment
in a trusted environment. This process is achieved by automati-
cally comparing patient information against computable eligibility
criteria in real-time during consultations. However, most of these
systems are bespoke [4, 1, 2], recruiting patients to a single trial
within a single clinic. Other similar techniques have also seen only
limited large-scale testing [13]. The challenge of designing generic
systems that can handle multiple trials is exacerbated by the com-
plexity of interactions between the various organisations. Trust and
security issues, for example, are significant, often hampering the
ability to deploy non-bespoke systems. Similarly, technical chal-
lenges such as scalability becomes notable when expanding deploy-
ments across multiple trials and clinics (eligibility criteria can be
extremely complicated to compute). All of these have meant that
CTA systems still remain in their infancy.
2.2 Agent Based Healthcare Systems
The use of agent-based systems for healthcare has seen widespread
investigation. Nealon et al. [9] discusses 11 areas in which agent
technology is being applied to improve healthcare in Europe, in-
cluding integration of heterogeneous patient records [8], control of
cardiac pacing, and monitoring the elderly using agent-based tele-
assistance. For example, MAID [3] is an agent-based system for
integrating heterogeneous data sources within a hospital environ-
ment. The studied hospital had 24 departments, each using their
own information systems. To address this, agents were constructed
to interoperate with each system to monitor changes and retrieve
data for insertion into a central repository. In a subsequent work,
HealthAgents [5] also enabled decision support, specifically for di-
agnosing brain tumours.
Agent-based systems have also been proposed for handling dis-
tributed expertise, such as using agents to enable better communi-
cation between healthcare workers based on ambient information,
e.g. their role, location etc. [12], as well as using agents to remotely
monitor patients [6, 11]. These systems often involved data analy-
sis. S(MA)2D, for instance, uses statistical analysis to cluster pa-
tients into similar groups [11]. This ability to scalably perform data
analysis in real time also shows potential for enabling the type of
eligible patient identification discussed previously. Despite this,
there has been little study into using agents to improve clinical trial
recruitment.
2.3 The GAIA Methodology
In our work, we have applied the GAIA agent-oriented software
engineering methodology to develop our agent-based system. The
GAIA methodology [15] was proposed to guide the process of de-
veloping a multi-agent system from analysis to design. For brevity,
we focus here on one particular model used in the methodology:
the role model. A role describes a particular agent behaviour, and
is defined in the form of a schema, which consists of the following
parts: description is used to briefly express the purpose of the role;
protocols and activities are the actions and tasks that the role are
provided with to achieve its goal and to communicate with other
roles; permissions specify the information that the role has access
to or able to produce; and, responsibilities define the generalised
behaviour pattern of the role (liveness) as well as states of affair
that the role must maintain or bring to existence (safety). Instances
of roles are shown as part of our design below.
3. MODELLING CLINICAL TRIALS
The first problem in designing a healthcare system like ePCRN-
IDEA is the diversity of languages and standards used within the
different key organisations. This problem has plagued many, often
unsuccessful, healthcare systems. To address this, our work started
with the construction of a formal model capable of capturing the
key attributes of clinical trials. This was chosen as it is the only
body of information that must consistently be understood across
all organisations. The key design goal of the model has been to
allow easy translation from existing data structures, better enabling
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Figure 1: Recruitment System Architecture
independent organisations to interoperate [14]. In contrast, the data
format of individual bi-lateral information flows can be defined by
the agents involved.
A full specification of the model is beyond the scope of this pa-
per, however, here we provide a brief overview to assist in general
understanding. The model can be separated into a number of sub-
models that collectively capture all important aspects of a trial’s
design. These can be summarised as follows:
• Trial Description: This model holds a description of a trial,
e.g. the title, overview, funding body etc. It allows practi-
tioners to be presented with details of the trial during the re-
cruitment phase. Much of the data in this model is therefore
free-text, which can be used to easily generate descriptions
for various entities (e.g. GPs, public websites, researchers).
• Eligibility Criteria: This model represents a formal com-
putable set of criteria for patient eligibility. It defines the
characteristics required of any participating patients. The
model is SQL-like in nature, allowing complex sets of pred-
icates to be executed over any fields in a patient’s medical
record. These predicates can be used to both include and ex-
clude a patient from recruitment. Typical predicates would
include age, gender and ailments (there are existing termi-
nology standards for describing ailments). Often, patients
with particular existing ailments or treatments would also be
excluded. Note that this model does not stipulate when or
where the criteria should be executed to compute eligible pa-
tients. For example, the criteria could be used in real-time
as patient data is entered or, alternatively, in batches every
month from a centralised database.
• Recruitment Model: This model stores information about the
recruitment process itself. It stipulates details such as how
many patients should ideally be recruited, which clinics are
authorised, which GPs are authorised, how patients should
be recruited if they are interested, the priority of recruiting
for the particular trial and recruitment timeplans. This is an
important component in allowing the agents to reason over
the finer-grained needs of the trial’s recruitment process.
These models were defined through collaboration between sev-
eral parties, including doctors, developers and medical and com-
puter science researchers. The models have been captured within
XML schemas that (as will be later discussed) are shared amongst
all agents and organisations, allowing each one to map their own
data to the trial schema.
4. SYSTEM DESIGN
The previous section has provided an overview of the way ePCRN-
IDEA models clinical trials. We exploit this model to enable agents
in different organisations to interoperate. This section now details
the design of ePCRN-IDEA, which we have decomposed into a
set of agents responsible for a variety of tasks. During our de-
sign process, we have followed the GAIA development method-
ology; as such, we also include, where appropriate, formal GAIA
descriptions of the agents. Due to space constraints, the interaction
between all the different agents is depicted on the overall system
design diagram and not through the interaction model diagrams of
GAIA.
Note that, although, we have developed our prototype for the
UK, we intend our design to be applicable for many different health-
care systems. As such, in this section, we wish to strictly separate
our design from implementation and, thus, endeavour to avoid spe-
cific implementation details. Instead, details of our prototype real-
isation of this design are delayed until Section 5.
4.1 Overview
As discussed in Section 1, the basic idea behind ePCRN-IDEA
is to place software agents within the primary care clinics (more
accurately, on GPs’ computers). These agents interact with a num-
ber of other humans and software agents to discover, recruit and
monitor patients who are eligible for any trials that exist within the
system. Figure 1 illustrates the architecture of the overall system,
where arrows indicate the interactions between agents, i.e. the flow
of information. To provide greater insight, the links are also anno-
tated with example operations that occur through these interactions.
Note that these are just examples and do not provide an exhaustive
set of interactions.
The process of trial recruitment begins with the Designing Agent.
This is an agent that resides within the organisation of the researcher.
The researcher is a human operator responsible for defining new
trials. The Designing Agent works with the researcher to gener-
ate an instantiation of the clinical trial model described in Sec-
tion 3. The Designing Agent then passes the newly created trial
model to one or more Trial Managing Agents. Many of these ex-
ist throughout the healthcare system available in the country; typ-
ically, these would be distributed in a geographical sense. In the
UK, for example, healthcare is split between multiple geographical
management groups termed primary care trusts (each would have
one agent). The Trial Managing Agents are responsible for coordi-
nating in which clinics recruitment should be performed (for each
trial). Once they have decided this, they pass the new trial model to
a set of Recruitment Agents. These exist on every GP’s computer
in every clinic. The Recruitment Agent monitors the data entry by
the GP to decide if any patient matches the eligibility criteria for
the trials it is aware of. If a match is observed, the Recruitment
Agent generates a graphical pop-up asking the GP to recruit the
patient. Obviously, this requires real-time access to patient infor-
mation, which is provided by a Patient Data Handler Agent. This
also sits on the GP’s computer, but is owned and managed by the
company that controls the patient’s medical records.1 Once some-
one has been recruited, an Execution Agent is contacted to initiate
the trial with the patient. In the simplest case, this might involve
retrieving information (e.g. a blood pressure reading), whereas in
other cases it could involve complex interventions (e.g. drug treat-
ments) accompanied by proactive data collection.
1In the UK, several commercial vendors provide Electronic Health
Record databases. Clinics are largely free to select their preferred
one.
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Below, we describe these agents in more detail, explaining their
responsibilities and relation with each other.
4.2 Designing Agent
Before any recruitment can take place, it is necessary for the re-
searcher to provide a comprehensive description of the trial for the
system. Most notably, this includes the formal eligibility criteria
for patient inclusion. This process is managed by the Designing
Agent, which we detail in Table 1 using a GAIA role model.
The Designing Agent resides within the organisation of the re-
searcher, e.g. a university or pharmaceutical company. It acts as
the representative of the researcher, and brokers interactions be-
tween the researcher and the wider ePCRN-IDEA system. Its key
task is to receive the trial description as identified by the researcher
(ReceiveCriteria) and express it in a systematic manner (Design-
Specification). In order to confirm that the specification expresses
the researcher’s generic criteria, a series of communications must
take place between the researcher and Designing Agent until the
researcher’s approval is received (AcknowledgeSpecification).
Following this, the Designing Agent must submit the newly cre-
ated trial to the rest of the system (DistributeSpecification). This
will often involve a variety of negotiations; the most prominent ex-
ample relates to the monetary charges that are issued (many entities
expect payment for their role, e.g. clinics). This negotiation can
also involve adaptation of the trial description within the ranges
stipulated by the researcher, e.g. lowering the desired number of
patient recruits. Note that often the researcher would want to be
involved in authorising these negotiations.
4.3 Trial Managing Agent
Once a Designing Agent has created a new trial description, it
is required to submit it to the system. This submission, and sub-
sequent negotiation, is received by one or more Trial Managing
Agents (ReceiveTrial). The functionality of this agent is captured
in the GAIA role model, shown in Table 2. The Trial Managing
Agents are responsible for coordinating the placement of trial re-
cruitment across all clinics under their control (DistributeTrial,).
The Trial Managing Agents exist throughout the heathcare sys-
tem(s) resident in the country. In the UK, there is a single inte-
grated healthcare system (the National Health Service). This, how-
ever, is separated into several organisational units termed primary
care trusts; each has independent management, legal constraints
and protocols to follow. To address this diversity, a Trial Manag-
ing Agent exists in each. Their key responsibility is to select in
which clinics a trial should be recruited for. Due to both legal and
scalability reasons, it is impossible for every trial to exist in every
clinic. As such, this must be a well thought out decision: some clin-
ics may have the potential to recruit tens of patients, whereas oth-
ers will be unable to recruit even a single one. Similarly, complex
inter-dependencies between trials must also be managed (Repriore-
tiseTrials and SuspendTrials). For example, trials with extremely
similar eligibility criteria should not recruit in the same clinic; this
is because the one with the higher priority would likely prevent
the other from recruiting (thereby making its presence redundant).
These decisions therefore require interaction between the different
Trial Managing Agents, as well as with the clinics themselves.
Following the deployment of the trials in the clinics, the Trial
Managing Agent is responsible for monitoring recruitment in their
area (MonitorRecruitment). This results in a feedback loop, allow-
ing trials to be re-allocated to different clinics where appropriate.
The Trial Managing Agents must also report back to the Design-
ing Agent so that the researcher can follow progress (ProvideFeed-
back). This can also result in adaptation of the trial description
itself. For example, one of the pilot trials in ePCRN-IDEA had its
criteria adapted after several weeks due to problems with recruit-
ment.
4.4 Recruitment Agent
Once the Trial Managing Agents have decided which clinics and
GPs should perform recruitment for a given trial, the details must
be sent to the clinics. This is received by the Recruitment Agents
(ReceiveTrial), which reside on the computers of any GPs autho-
rised for recruitment. The functionality of the Recruitment Agent
are captured in the GAIA Role model presented in Table 3.
The Recruitment Agents act as mediators between the patient,
the GP and the trial itself. Its key responsibility is to discover and
recruit patients in the clinic for the trials it knows of. Whenever a
patient visits a clinic, the GP enters information into their patient
database, e.g. about new diagnoses. This information is passed to
the local Recruitment Agent (ReceivePateintData) (via the Patient
Data Handler Agent) and used to compute the patient’s eligibility
for any known trials (CheckEligibility). For example, a drug trial
looking to test a new treatment on people with joint pain would
clearly need patients who are complaining of joint pain.
Once a Recruitment Agent has computed the trials that a pa-
tient is eligible for, it is responsible for ensuring that a recruitment
takes place. Through user interviews and experimentation, we have
found that GPs are often very reluctant to expend time and cogni-
tion on dealing with recruitment whilst a patient is in consultation.
As such, the Recruitment Agent is driven towards only presenting
trials that it believes will result in recruitment. Whenever a set of
eligible trials is computed, the Recruitment Agent is tasked with
selecting which to display, i.e. prioritising them (RankTrials). This
is based on trial-specific factors (e.g. the trial’s urgency), as well as
GP-specific factors (e.g. the types of trials the GP is interested in).
If the patient is interested in recruitment, the GP is can confirm
it with the Recruitment Agent (RecruitPatinet). Following this, the
Recruitment Agent must contact the Trial Managing Agent to in-
form it of the update (NotifyManagingAgent), and the Execution
Agent to start the follow up process (NotifyExecutionAgent).
4.5 Patient Data Handler Agent
To enable the Recruitment Agent to fulfil its task, it is neces-
sary to provide it with real-time information about patients during
their consultation. Although simplistic in many domains, this is
extremely difficult in healthcare due to the sensitivity of data. The
responsibility of managing patient data is therefore given to the
Patient Data Handler Agent. The functionality of this agent is pre-
sented in the GAIA role model, shown in Table 4.
The Patient Data Handler Agent resides alongside every Recruit-
ment Agent in the clinic. It is owned and managed by the Elec-
tronic Health Record database proprietor, as a separate entity to
the other key organisations (note that several proprietors exist in
the UK). Whenever requested (ReceiveRequest), the Patient Data
Handler Agent provides information about the patient in question
(ExtractData and InformRecruitment). This requester is most fre-
quently the local Recruitment Agent itself, however, it may also
be a Trial Designing Agent or a Trial Managing Agent, which also
use patient data. The key task undertaken by the Patient Data Han-
dler Agent is ensuring privacy is not undermined. This is achieved
by executing various privacy policies on data requests, restricting
access to authorised users. Im
4.6 Execution Agent
The previously described agents have been primarily responsi-
ble for recruiting patients into a clinical trial. However, the process
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Table 1: The Designing Agent Role Model
Role Schema: Designing Role
Description: This role involves designing clinical trial specifications that satisfy with researcher’s requirements.
Protocols and Activities: ReceiveCriteria, DesignEligibilityCriteria, DesignRecruitmentCriteria, DesignSpecification, DistributeSpeci-
fication, AcknowledgeSpecification
Permissions: reads researcherCriteria // the criteria of the trial
generates trialSpecification // the complete design of trial
Responsibilities:
Liveness: DesingTrial= (ReceiveCriteria.DesignSpecification.DistributeSpecification)ω
DesignSpecification = (DesignEligibilityCriteria.DesignRecruitmentCriteria.AcknowledgeSpecification)ω
Safety: equivalent(ClinicalTrial , researcherCriteria)
Table 2: The Trial Managing Role Model
Role Schema: Trial Managing Agent
Description: This role involves monitoring the recruitment for clinical trials within certain geographical location.
Protocols and Activities: ReceiveTrial, MonitorRecruitment, DistributeTrial, ReprioretiseTrials, SuspendTrials, CheckStatus, Provide-
Feedback
Permissions: reads trialRecruitmentStatus // the current recruitment status of a trial
deactivate trialID // the identifier of clinical trial
Responsibilities:
Liveness: Trial = (ReceiveTrial.DistributeTrial.MonitorRecruitmentω .ProvideFeedback)ω
MonitorRecruitment = (CheckStatus.(ReprioretiseTrials|SuspendTrials).InformRecruitmentAgent)ω
Safety: ReachedTrialDeadline = true => trialRecruitment >= targetRecruitment
does not end there. Depending on the trial, there may be multi-
ple phases that the patient needs to go through: few trials are only
about collecting some static information about the patient. Conse-
quently, it is necessary to monitor the execution of the trial across
its multiple phases, making sure that all the phases’ goals are met
and the result are collected and analysed. The Execution Agent is
therefore responsible for executing the trial itself; a formal descrip-
tion of its functionalities is provided in Table 5. A huge number of
Execution Agents could exist (in theory, one per trial). In the sim-
plest case, they could request the retrieval of periodic information
about a given patient. However, this could also involve instructing
GPs to perform various (changing) interventions (CheckPhases).
Clearly, the final responsibility of the Execution Agent is collating
the collected data (ObtainResult) and providing it to the researcher
(InformResearcher).
5. PROTOTYPE IMPLEMENTATION
The previous section has presented the design of ePCRN-IDEA.
We now detail our prototype realisation of this design, which we
have deployed across 31 clinics in the UK. So far, we have imple-
mented a subset of the overall architecture, replacing certain agents
with simpler alternatives. Several organisations have been involved
in this process, including universities, clinics, companies and gov-
ernment organisations. Each, as discussed in the previous section,
plays an integral role in achieving the overall system goal. The
agents have been implemented as follows:
• Designing Agent: The Designing Agent has been implemented
within a Workbench toolkit that is provided to researchers.
This allows the authoring and submission of new trials. Cur-
rently, the Designing Agent only exists in a single research
organisation: the UK’s Clinical Practice Research Datalink
(CPRD). They are currently running a number of active clin-
ical trials that ePCRN-IDEA is facilitating with. The nego-
tiation process between the Designing Agent and the rest of
ePCRN-IDEA is currently quite rudimentary, with all trials
that match authorisation policies being accepted. Similarly,
all monetary transactions are performed external to the sys-
tem. Clearly, the prioritised future work for this agent is en-
hancing its negotiation capabilities to reduce the need for any
external interactions between parties.
• Trial Managing Agent: The Trial Managing Agent has been
implemented in Java, with support from a MySQL back-end
database. This is used to conveniently exchange trial infor-
mation in a secure way. Due to the legal constraints on such
systems, these types of security considerations were vital for
achieving deployment. Due to the relatively small number of
pilot clinics (31), only one Trial Managing Agent currently
has been instantiated. It operates within King’s College Lon-
don (technical coordinators of the system). Within the pro-
totype, its current responsibilities centre on the distribution
of trials, as well as the collection of progress information.
The latter is used to activate and deactivate recruitment, as
well as feed information back to the Designing Agent for in-
terested researchers. The key future work of interest to us
is scaling the number of Trial Managing Agents up, and en-
abling their interaction, which currently we do not support.
Unfortunately, due to the need to first increase the number of
clinics, we are investigating these principles via simulation.
• Recruitment Agent: The Recruitment Agent has been imple-
mented in Java and has been used by 124 GPs so far. Despite
obvious deployment challenges, it has largely been well re-
ceived with many practitioners keen to be involved. This
agent has been the key focus of our work so far, and cur-
rently supports all the tasks detailed in the earlier design.
Figure 2 provides a screenshot of the Recruitment Agent’s
graphical pop-up. Through experimentation, we discovered
that most GPs were only prepared to be presented with a sin-
gle trial alert (rather than the original list of several that we
provided). As such, the Recruitment Agent only displays the
highest priority one. The GP is then allowed to register sev-
eral responses, as shown in Figure 2. All inter-agent inter-
action is then automatically handled, without requiring any
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Table 3: The Recruitment Role Model
Role Schema: Recruitment Agent
Description: This role involves checking the eligibility of patients for clinical trial.
Protocols and Activities: ReceiveTrial, ReceivePateintData, CheckEligibility, RankTrials, NotifyGP, RecruitPatinet, NotifyManagin-
gAgent, NotifyExecutionAgent
Permissions: reads: trialData // The trial criteria
patientReleventData // the data of the patient
generate: notification // notification about patient’s eligibility
Responsibilities:
Liveness:
PateintRecruitment = (ReceivePateintData.CheckEligibility.RankTrials.RecruitPatinet.NotifyManagingAgent.NotifyExecutionAgent)ω
Safety: RecruitedPatinet => EligiblePatient
Table 4: The Patient Data Handler Role
Role Schema: Patients Data Handler Role
Description: This role involves maintaining patient data across multiple consultations, and extracting trial relevant data and send it to
the recruitment agent
Protocols and Activities: ReceiveRequest, ExtractData, InformRecruitment
Permissions: reads: patientData
Responsibilities:
Liveness: PateintDetection = (ReceiveRequest,CheckPatient.InformRecruitment)ω
external actions by the user.
• Patient Data Handler Agent: The Patient Data Handler Agent
has so far been implemented within a single Electronic Health
Record system called Vision. This has been performed by
the proprietor, a company called INPS. Vision covers about
20% of all UK clinics. So far, it does not perform the ad-
vanced functionality in our design, instead, passing a fixed
set of patient attributes to the Recruitment Agent whenever
a new patient record is opened or changed during a consul-
tation. To pass information from the Patient Data Handler
Agent to the Designing Agent and Trial Managing Agent,
a central database hosted at CPRD is used as an intermedi-
ary. Once again, this is necessary to satisfy the tight security
requirements on our deployment: for a prototype it was con-
sidered unacceptable to send confidential patient information
to multiple agents in different organisations in an entirely au-
tomated way (note that CPRD has a trusted position, hence
this choice). Clearly, our key future work is therefore to
overcome these regulatory challenges and enable more direct
inter-agent communication of such data. Further, we wish to
expand the privacy controls within the Patient Data Handler
Agent as a key component of enabling this.
• Execution Agent: The Execution Agent is an agent that is
developed on a per-trial basis. This is because different tri-
als can have wildly different needs for their execution. We
currently have the functionality of the Execution Agent split
between a bespoke website developed by a third party com-
pany and a special department within CPRD. Collectively,
these are responsible for performing the management tasked
detailed in the design. For example, they study the status of
the patients, and issue appropriate instructions to GPs for any
necessary interventions (e.g. changes in drug treatments).
6. EVALUATION
The previous section has described our prototype deployment
of ePCRN-IDEA. Due to the novelty of such real-world deploy-
ments, we choose to focus our evaluation on the results gained
Table 6: Description of Deployed Trials
Trial Name Description
eLung
The eLung trial targets patients aged over 40
with a medical history of Chronic Obstructive
Pulmonary Disease (COPD) who, in the opin-
ion of the GP, had an acute exacerbation of
COPD with an increase of non-purulent sputum
volume, who did not require immediate referral
to specialist care for treatment of COPD exac-
erbation and consented to participation.
RETROPRP
Retropro is a pragmatic point-of-care trial, and
target patients with age over 40, a 20% or
greater 10-year risk of developing CVD, pri-
mary hypercholesterolemia and consent to par-
ticipation.
FLU-CATs
The FLU-CATs study evaluates and refines
community assessment tools for use as decision
aids in preparation for any future influenza pan-
demic or similar event where health-seeking be-
haviour exceeds clinical capacity.
through this. More specifically, we ask the question: has ePCRN-
IDEA been successful in improving recruitment? Due to space con-
straints, we do not explore the more technical components (e.g.
overheads).
So far, the Recruitment Agent has been installed in 31 clinics
with 124 GPs involved. We have been successful in initiating three
(diverse) clinical trials within the system, summarised in Table 6.
We have found that all GPs involved recruited at least one patient.
Overall, ePCRN-IDEA has generated 3204 alerts, with 230 pa-
tients being recruited (7.1%). Although, at first, this may not seem
significant, it is actually far above the recuitment levels one would
likely achieve through traditional means, e.g. advertisements. In-
terestingly, we also found that 45 of these alerts resulted in the GP
deciding that the patient was not actually eligible. This verifies
the point raised by a number of clinicians throughout the develop-
ment of ePCRN-IDEA, which is that the agents must always oper-
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Table 5: The Execution Role Model
Role Schema: Execution Agent
Description: This role involves monitoring the execution of a clinical trial after a patient has been recruited.
Protocols and Activities: ReceiveTrial, ReceivePatient, CheckPhases, ObtainResult, InformResearcher
Permissions: reads: trialData
Responsibilities:
Liveness: TrialExecution = (ReceivePatient.CheckPhases .ObtainResult.InformResearcher)ω
Safety: PhaseDeadlineReached= true => PhasesResultObtained = true
ate within the confines of human supervision. In terms of patients’
responses (other than acceptance) 30 patients were not interested
and 14 patients wanted time to think. This means that the major-
ity of alerts were actually ignored by the GP, suggesting that many
unwanted interrupts could (and should) have been avoided by the
Recruitment Agent. We believe this warrants further work to ensure
that Recruitment Agents are able to learn when to best interrupt the
GP with an alert (if at all). That said, despite being offered, none of
the participating GPs requested that the recruiting agent be stopped.
A summary of results is shown in Table 7.
 
Figure 2: GP Notification Respond Interface
Whereas overall we noted positive results from the trials, we also
observed significant variations between the behaviour of the differ-
ent trials. To explore this, Figure 3 shows the number of notifica-
tions generated per-month between January and September of 2013
(note that FLU-CATS only started in the second month). It can be
seen that ePCRN-IDEA was effective at generating notifications
for all trials, particularly RETROPRO during the later months. This
dramatic increase occurred due to a re-definition of the eligibility
criteria. We found that ePCRN-IDEA’s management mechanisms
(e.g. the Trial Manager Agent) were vital for achieving this re-
definition, which was brought about because many GPs were not
entering the properly formatted information into their Electronic
Health Record database, instead using quick free-text (RETROPRO
was the only trial that needed this). To address the issue, the trial
researchers adapted the eligibility criteria to use a pre-computed
list of ‘at-risk’ patients instead. This therefore generated pop-ups
whenever the patient’s record was opened. As can be seen, this re-
sulted in a spike in recruitment, achieving over 40 new recruits at its
peak. This highlights effectively the flexibility of the trial models
used, as well as the ability of the architecture to monitor and react
to behaviour in the system (in collaboration with its human oper-
ators). The relationship between the notifications and recruitment
can also be seen in Figure 4. As can be observed from this figure,
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Figure 3: Number of Notifications Generated Over Time
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Figure 4: Number of Recruited Patients Over Time
some trials managed to recruit more patients than others, although
overall a roughly positive trend can be seen across all cases. The
trial with the greatest number of recruits is FLU-CATs, as this has
only a very low overhead for the patients.
Through these results, we would argue that there have been very
real benefits offered by ePCRN-IDEA. By decomposing the system
into self contained agents, this has also been achieved in a way
that has satisfied the various stakeholders by empowering them to
(internally) operate in a way that matches their personal needs and
norms. Practically speaking, without this, the deployment would
likely have not taken place.
7. CONCLUSION AND FUTURE WORK
This paper has detailed the design, implementation and deploy-
ment of an agent-based system called ePCRN-IDEA. The research
started in an attempt to devise novel ways in which technology
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Table 7: Detailed Observation of the three trials
Trial ID eLung RETROPRP FLU-CATs
Start date 21-01-2013 19-01-2013 28-01-2013
Result reporting date 30-09-2013 30-09-2013 30-09-2013
Number of flags 914 1589 569
Number of patients recruited 40 31 149
Number of patients not interested 10 6 14
Number of patients not eligible 25 18 2
Number of patients who need time to think 1 6 7
could facilitate the recruitment of patients to clinical trials. We
quickly realised, however, that the complexity and cross-organisational
nature of the domain would make traditional software architectures
difficult to use in practice. As such, we have built and deployed
a comprehensive agent-based design that has already managed to
recruit 230 patients to three pilot trials in operation. Our evaluation
so far has centred on the ability of ePCRN-IDEA to enable superior
recruitment. It has verified that both the technology and the under-
lying principles are correct, and that systems such as this have a
great potential. It has also highlighted the flexibility of our archi-
tecture, allowing the agents and human operators to adapt to reflect
new observations (e.g. adapting eligibility criteria in response to
user behaviour).
A critical point to raise, however, is the disparity between our
system design and the prototype implementation. Whilst we have
built a range of sophisticated algorithms into our agent design, we
have not been able to integrate all of them into our deployment.
The reasons for this have been diverse, and warrant discussion in
themselves. At one end of the scale, in some cases, we did not have
sufficient manpower to realise their complexity. However, in the
majority of cases, this exclusion was the product of legal and se-
curity constraints brought about by the nature of the domain. The
focus for future work is therefore to further our prototype by re-
placing the simpler agent implementations with that originally de-
tailed in the design. Of most priority are the Patient Data Handler
Agent and the Execution Agent. Beyond this, we are also contin-
ually working on all the existing agent prototypes to increase their
sophistication; of most interest is the deployment of multiple Trial
Management Agents to better realise their potential for collabora-
tion when managing the placement of trial recruitment amongst the
different trials. Clearly, alongside this technical future work, we
are also working towards the expansion of our pilot by including
increasing numbers of clinics and trials. Our final aim is then to
achieve a full system evaluation that explores the intricacies of the
agents in in wild.
8. REFERENCES
[1] L. B. Afrin, J. C. Oates, C. K. Boyd, and M. S. Daniels.
Leveraging of open emr architecture for clinical trial accrual.
AMIA Annual Symposium proceedings AMIA Symposium
AMIA Symposium, 2003:16–20.
[2] A. J. Butte, D. A. Weinstein, and I. S. Kohane. Enrolling
patients into clinical trials faster using realtime recuiting.
Proceedings of the AMIA Symposium, pages 111–115, 2000.
[3] R. Cruz-Correia, P. Vieira-Marques, P. Costa, A. Ferreira,
E. Oliveira-Palhares, F. Araújo, and A. Costa-Pereira.
Integration of hospital data using agent technologies - a case
study. AI Commun., 18, August 2005.
[4] P. J. Embi, A. Jain, J. Clark, S. Bizjack, R. Hornung, and
C. M. Harris. Effect of a clinical trial alert system on
physician participation in trial recruitment. Archives of
Internal Medicine, 165(19):2272–2277, 2005.
[5] H. González-Vélez, M. Mier, M. Julià-Sapé, T. Arvanitis,
J. García-Gómez, M. Robles, P. Lewis, S. Dasmahapatra,
D. Dupplaw, A. Peet, C. Arús, B. Celda, S. Van Huffel, and
M. Lluch-Ariet. Healthagents: distributed multi-agent brain
tumor diagnosis and prognosis. Applied Intelligence, 30,
2009.
[6] V. Koutkias, I. Chouvarda, and N. Maglaveras. A multiagent
system enhancing home-care health services for chronic
disease management. Information Technology in
Biomedicine, IEEE Transactions on, 9(4):528–537, dec.
2005.
[7] A. McDonald, R. Knight, M. Campbell, V. Entwistle,
A. Grant, J. Cook, D. Elbourne, D. Francis, J. Garcia,
I. Roberts, and C. Snowdon. What influences recruitment to
randomised controlled trials? a review of trials funded by
two uk funding agencies. Trials, 7(1):9, 2006.
[8] M. Nagy and M. Vargas-Vera. Towards an Automatic
Semantic Data Integration: Multi-agent Framework
Approach. Chapter in Sematic Web. In-Tech Education and
Publishing KG, 2010.
[9] J. Nealon. Agents applied in health care. AI
Communications, page 22, 2005.
[10] R. Nitkin. Patient recruitment strategies. Training workshop
conducted by National Institutes of Health, Bethesda, Md,
2003.
[11] A. Rammal, S. Trouilhet, N. Singer, and J.-M. Pécatte. An
adaptive system for home monitoring using a multiagent
classification of patterns. Int. J. Telemedicine Appl.,
2008:3:1–3:8, January 2008.
[12] M. D. Rodríguez, J. Favela, A. Preciado, and A. Vizcaíno.
Agent-based ambient intelligence for healthcare. AI
Commun., 18:201–216, August 2005.
[13] B. L. Rollman, G. S. Fischer, F. Zhu, and B. H. Belnap.
Comparison of electronic physician prompts versus
waitroom case-finding on clinical trial enrollment. Journal of
General Internal Medicine, 23(4), 2008.
[14] G. Tyson, A. Taweel, S. Zschaler, T. V. Staa, and B. Delaney.
A model-driven approach to interoperability and integration
in systems of systems. In Proc. of Workshop on Model-Based
Software and Data Integration (MBSDI), 2011.
[15] M. Wooldridge, N. R. Jennings, and D. Kinny. The gaia
methodology for agent-oriented analysis and design. Journal
of Autonomous Agents and Multi-Agent Systems, 3:285–312,
2000.
988
